Amedel - General Information
An antineoplastic agent that acts by alkylation.
Pharmacology of Amedel
Amedel is an antineoplastic agent. Specifically it is a piperazine derivative with a chemical structure close to that of many DNA alkylating agents. Amedel has well documented clinical activity against polycythemia vera and essential thrombocythemia.
Amedel for patients
Children under 15 years of age. Lactation. Bone marrow depression due to chemotherapy or X rays.
Additional information about Amedel
Amedel Indication: For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.
Mechanism Of Action: The mechanism of action is uncertain but pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.
Drug Interactions: Acebutolol Antagonism
Food Interactions: Not Available
Generic Name: Pipobroman
Synonyms: Not Available
Drug Category: Antineoplastic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Pipobroman: Amedel; Vercyte;
Absorption: Well absorbed from the GI tract.
Toxicity (Overdose): Symptoms of overdose include hematologic toxicity, especially with chronic overdosage.
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Amedel: Not Available
Chemical IUPAC Name: 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
Chemical Formula: C10H16Br2N2O2
Pipobroman on Wikipedia: http://en.wikipedia.org/wiki/Pipobroman
Organisms Affected: Humans and other mammals